Newsroom
Lifecore Biomedical, Inc Faces Securities Law Violations Lawsuit
By KlickAnalytics Data Insights | August 1, 2024 08:08PM ET
Key Points
- Shareholder filed a class action against Lifecore Biomedical between October 7, 2020, and March 19, 2024
- Multiple law firms, including Rosen Law Firm and Pomerantz LLP, are involved in the lawsuit
- The class action lawsuit is filed in the United States District Court for the District of Minnesota
- Investors who purchased Lifecore securities during the Class Period are encouraged to participate in the lawsuit
- The lawsuit alleges violations of federal securities laws by Lifecore and its top officials
Lifecore Biomedical, Inc is facing legal challenges as multiple law firms have filed class action lawsuits against the company for alleged violations of federal securities laws. A shareholder initiated a class action on behalf of all purchasers of securities of Lifecore Biomedical between October 7, 2020, and March 19, 2024. The lawsuit, docketed under 24-cv-03028 in the United States District Court for the District of Minnesota, aims to recover damages caused by violations of the federal securities laws by the company and certain officials.
Law firms such as Rosen Law Firm, Pomerantz LLP, and The Law Offices of Frank R. Cruz are actively involved in representing shareholders with losses on their investments in Lifecore Biomedical. The class action seeks remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 against the company and its top executives. Shareholders who purchased Lifecore securities during the Class Period are urged to contact these law firms before September 27, 2024, to discuss their rights and potential participation in the lawsuit.
The Schall Law Firm and Robbins Geller Rudman & Dowd LLP are also inviting investors who purchased Lifecore Biomedical securities between October 7, 2020, and March 19, 2024, to seek appointment as lead plaintiffs in the class action lawsuit. The lawsuit alleges violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Investors with substantial losses due to their investments in Lifecore Biomedical have the opportunity to lead the class action lawsuit and seek damages for the alleged violations.
Lifecore Biomedical, Inc investors are facing a significant legal battle as multiple class action lawsuits are being filed against the company for violations of federal securities laws. Shareholders who purchased Lifecore securities between October 7, 2020, and March 19, 2024, are encouraged to contact various law firms representing them before September 27, 2024, to discuss their rights and potential involvement in the lawsuits. The allegations include violations of the Securities Exchange Act of 1934 by the company and certain top officials, highlighting the importance of shareholder participation in seeking justice for any potential wrongdoing.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with